At the time of writing, Helius Medical Technologies Inc [HSDT] stock is trading at $0.75, down -6.48%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HSDT shares have gain 15.73% over the last week, with a monthly amount glided 56.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Helius Medical Technologies Inc [NASDAQ: HSDT] stock has seen the most recent analyst activity on March 24, 2021, when Noble Capital Markets initiated its Outperform rating and assigned the stock a price target of $20.
For the past year, the stock price of Helius Medical Technologies Inc fluctuated between $0.37 and $9.50. Helius Medical Technologies Inc [NASDAQ: HSDT] shares were valued at $0.75 at the most recent close of the market.
Analyzing the HSDT fundamentals
According to Helius Medical Technologies Inc [NASDAQ:HSDT], the company’s sales were 0.50M for trailing twelve months, which represents an -64.34% plunge. Gross Profit Margin for this corporation currently stands at -0.06% with Operating Profit Margin at -25.9%, Pretax Profit Margin comes in at -17.65%, and Net Profit Margin reading is -17.65%. To continue investigating profitability, this company’s Return on Assets is posted at -1.59, Equity is -2.45 and Total Capital is -3.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7248 points at the first support level, and at 0.6987 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7923, and for the 2nd resistance point, it is at 0.8337.
Ratios To Look Out For
It is important to note that Helius Medical Technologies Inc [NASDAQ:HSDT] has a current ratio of 3.61. As well, the Quick Ratio is 3.09, while the Cash Ratio is 2.32. Considering the valuation of this stock, the price to sales ratio is 5.60, the price to book ratio is 0.72.
